Sanofi (SNY) said Friday the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma adult patients eligible for autologous stem cell transplant.

The approval followed a positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use last month, the company said.

Sarclisa is now approved in the EU across all lines of therapy, regardless of transplant eligibility, Sanofi said.

Price: 49.91, Change: -0.22, Percent Change: -0.44